NewMoneyMoves
PerspectivesResearchTerminalsWeekend RWABoard
HomeThemesK-Bio & Drug DevelopmentBio CDMO

Bio CDMO

The biopharmaceutical CDMO (Contract Development and Manufacturing Organization) market is growing 10%+ annually. Samsung Biologics, Lonza, and WuXi Biologics are competing for global capacity, while complex production processes for next-gen biologics like ADCs and bispecific antibodies are structurally expanding CDMO demand.

Updated: 2/25/202612-24 months

Investment Confidence

Confidence Index88%
LowMediumHigh

Theme Analysis

Key Drivers

  • Global CDMO market growing 10%+ annually
  • Growing demand for complex drug production (ADC, bispecific antibodies)
  • Big pharma outsourcing ratio expanding
  • Samsung Biologics achieving global #1 capacity with Plant 5

Risk Factors

  • WuXi Biologics and other Chinese CDMOs' price competition
  • Biotech investment slowdown reducing orders
  • Large capex recovery uncertainty
  • Quality issues risking major contract termination

Catalysts

  • Samsung Biologics new large-scale order announcement
  • ADC pipeline clinical success expanding CDMO demand
  • De-China shift benefiting Korean CDMOs amid WuXi regulatory risk

Related Investment Ideas

No related investment ideas yet

New ideas will appear here when available

Related Reports

1
Theme Deep-Dive
7/5/202615 min read

The K-Bio Map — Out-Licensing, CDMO, Obesity Drugs: Three Investable Axes

2025 out-licensing topped KRW 20 trillion for the first time. The index fell double digits in the first half, but capacity, platform, and the patent cliff stand as three distinct cash-flow structures.

Comments

Created: 2/25/2026Updated: 2/25/2026
Related Assets
Samsung Biologics
Direct Exposure
Relevance 95%
Lonza
Competitor
Relevance 85%
WuXi Biologics
Competitor
Relevance 80%
Catalent
Competitor
Relevance 70%
Quick Stats
Confidence88%
Investment Period12-24 months
Investment Ideas0
Related Reports1
Report Shortcuts
Theme Deep-Dive
The K-Bio Map — Out-Licensing, CDMO, Obesity Drugs: Three Investable Axes
15 min read
Parent Theme
Mega Theme
K-Bio & Drug Development
NewMoneyMoves

Global Investment through Themes

Content

ThemesIdeasReportsEarnings

Explore

GuideETFsPerspectivesTelegramNVIDIA PortfolioWeekly ReviewCredit & Leverage

Community

Daily News

Legal

Privacy PolicyTerms of ServiceDisclaimer

© 2026 NewMoneyMoves. All rights reserved.